Note 3 - Net Loss Per Share	12 Months Ended
Jan. 01, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 3 — NET LOSS PER SHARE Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share was computed using the weighted average number of common shares outstanding during the period plus potentially dilutive common shares outstanding during the period under the treasury stock method. In computing diluted net loss per share, the weighted average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options and warrants. Approximately 0.8 million shares, 0.7 million shares, and 0.9 million shares associated with equity awards outstanding and the estimated number of shares to be purchased under the current offering period of the ESPP Plan were not included in the calculation of diluted net loss per share, as they were considered antidilutive due to the net loss the Company experienced in the years ended January 1, 2023, January 2, 2022 and January 3, 2021, respectively. Warrants to purchase up to 0.4 million shares were issued in connection with May 29, 2018 stock offering were also not included in the diluted loss per share calculation as they were also considered anti-dilutive due to the net loss the Company experienced in the years ended January 1, 2023, January 2, 2022 and January 3, 2021.

Note 3 - Net Loss Per Share

12 Months Ended

Jan. 01, 2023

NOTE 3 — NET LOSS PER SHARE

Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share was computed using the weighted average number of common shares outstanding during the period plus potentially dilutive common shares outstanding during the period under the treasury stock method. In computing diluted net loss per share, the weighted average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options and warrants.

Approximately 0.8 million shares, 0.7 million shares, and 0.9 million shares associated with equity awards outstanding and the estimated number of shares to be purchased under the current offering period of the ESPP Plan were not included in the calculation of diluted net loss per share, as they were considered antidilutive due to the net loss the Company experienced in the years ended January 1, 2023, January 2, 2022 and January 3, 2021, respectively. Warrants to purchase up to 0.4 million shares were issued in connection with May 29, 2018 stock offering were also not included in the diluted loss per share calculation as they were also considered anti-dilutive due to the net loss the Company experienced in the years ended January 1, 2023, January 2, 2022 and January 3, 2021.